Advanced Search
GAO Jiankun, LONG Bo, ZENG Bin, TANG Xu. Effect of CRM1 Inhibitor KPT-185 on Growth of Human Prostate Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 676-680. DOI: 10.3971/j.issn.1000-8578.2015.07.008
Citation: GAO Jiankun, LONG Bo, ZENG Bin, TANG Xu. Effect of CRM1 Inhibitor KPT-185 on Growth of Human Prostate Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 676-680. DOI: 10.3971/j.issn.1000-8578.2015.07.008

Effect of CRM1 Inhibitor KPT-185 on Growth of Human Prostate Cancer Cells

More Information
  • Received Date: July 20, 2014
  • Revised Date: September 05, 2014
  • Objective To investigate the effect of chromosome maintenance region 1(CRM1) inhibitor KPT-185 on the growth, migration and apoptosis of prostate cancer cells and related reasons. Methods MTT assay, Clonogenic assay, Wound healing assay, flow cytometry analysis, Histone/DNA ELISA, Annexin V-FITC method and Western blot were used to detect KPT-185 effect on cell growth, migration, cell cycle, apoptosis, protein expression in prostate cancer cells and the potential mechanism, respectively. Results KPT-185 induction of cell apoptosis, growth inhibition and cell cycle arrest was involved in CRM1 inhibition and nuclear retention of tumor suppressor proteins p53 and p21 in prostate cancer cells. Conclusion KPT-185 as a new CRM1 inhibitor could be a potential drug in the treatment for prostate cancer.
  • [1]
    Fox AM, Ciziene D, McLaughlin SH, et al. Electrostatic interactions involving the extreme C terminus of nuclear export factor CRM1 modulate its affinity for cargo[J]. J Biol Chem, 2011, 286(33): 29 325-35.
    [2]
    Fornerod M, Ohno M, Yoshida M, et al. CRM1 is an export receptor for leucine-rich nuclear export signals[J]. Cell, 1997, 90 (6): 1051-60.
    [3]
    Kutay U, Izaurralde E, Bischoff FR, et al. Dominant-negative mutants of importin-beta block multiple pathways of import and export through the nuclear pore complex[J]. EMBO J, 1997, 16 (6): 1153-63.
    [4]
    Stade K, Ford CS, Guthie C, et al. Exportin 1 (Crm1p) is an essential nuclear export factor[J]. Cell, 1997, 90(6): 1041-50.
    [5]
    Strambio-De-Castillia C, Niepel M, Rout MP. The nuclear pore complex: bridging nuclear transport and gene regulation[J]. Nat Rev Mol Cell Biol, 2010, 11(7): 490-501.
    [6]
    Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond[J]. Trends Cell Biol, 2007, 17(4): 193-201.
    [7]
    Sakakibara K, Saito N, Sato T, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity[J]. Blood, 20 11, 118(14): 3922-31.
    [8]
    Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer[J]. Curr Med Chem, 2008, 15 (26): 2648-55.
    [9]
    Gao J, Azmi AS, Aboukameel A, et al. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer[J]. Oncotarget, 2014, 5(11): 34 44-54.
    [10]
    Levine AJ. p53, the cellular gatekeeper for growth and division[J]. Cell, 1997, 88(3): 323-31.
    [11]
    Vogelstein B, Lane D, Levine AJ. Surfing the p53 network[J]. Nature, 2000, 408(6810): 307-10.
    [12]
    Vousden KH, Lu X. Live or let die: the cell's response to p53 [J]. Nat Rev Cancer, 2002, 2(8): 594-604.
    [13]
    Fridman JS, Lowe SW. Control of apoptosis by p53[J]. Oncogene, 20 03, 22(56): 9030-40.
    [14]
    Vurusaner B, Poli G, Basaga H. Tumor suppressor genes and ROS: complex networks of interactions[J]. Free Radic Biol Med, 2012, 52 (1): 7-18.
    [15]
    Dotto GP. p21 (WAF1/Cip1): more than a break to the cell cycle? [J] Biochim Biophys Acta, 2000, 1471(1): M43-56.
    [16]
    Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis[J]. Mol Cancer Ther, 2002, 1(8): 63 9-49.
    [17]
    Li R, Waga S, Hannon GJ, et al. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair[J]. Nature, 1994, 371(6497): 534-7.
    [18]
    Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases[J]. Cell, 1993, 75(4): 805-16.
    [19]
    Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases[J]. Nature, 1993, 366(6456): 701-4.
    [20]
    el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression[J]. Cell, 1993, 75(4): 817-25.
    [21]
    Liu R, Wang L, Chen G, et al. FOXP3 up-regulates p21 expression by sitespecific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus[J]. Cancer Res, 2009, 69(6): 22 52-9.
    [22]
    Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53?[J]. Biol Cell, 2006, 98(3): 141-52.
  • Related Articles

    [1]ZENG Kai, LIU Jihong, LI Qiang, WANG Qinzhang. Research Progress of Lipid Metabolism Reprogramming in Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 774-779. DOI: 10.3971/j.issn.1000-8578.2022.21.1546
    [2]LI Ning, XIAO Guoyou. Advances in Treatment of Patients with Prostate Cancer Bone Metastases[J]. Cancer Research on Prevention and Treatment, 2020, 47(8): 641-646. DOI: 10.3971/j.issn.1000-8578.2020.19.1141
    [3]ZHANG Qiang, SUN Lijiang, ZHANG Guiming, QI Jun, YANG Zhigang. Influence of Periprostatic Adiposity Measurement Parameters on Preoperative Staging and Grading of Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(7): 488-491. DOI: 10.3971/j.issn.1000-8578.2018.17.1382
    [4]CHEN Lieqian, TAN Guobin, CHEN Hege, LIU Jianjun. Nitric Oxide-donor Drugs and Prostate Cancer: An Update[J]. Cancer Research on Prevention and Treatment, 2016, 43(2): 162-166. DOI: 10.3971/j.issn.1000-8578.2016.02.014
    [5]ZHANG Yingying, HU Bing, CHEN Lei. Laser Interstitial Thermotherapy in Treatment of Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(01): 82-85. DOI: 10.3971/j.issn.1000-8578.2015.01.020
    [6]PING Hao, ZHANG Jun-hui, CHEN Xiao-chun, LU Gong-cheng. Study on Inhibition of Growth and Proliferation in Prostate Cancer Cell by the shRNA of hTERT[J]. Cancer Research on Prevention and Treatment, 2007, 34(02): 128-131. DOI: 10.3971/j.issn.1000-8578.1535
    [7]CHEN Jiang, CHEN Xiao chun, ZENG Fu qing. Experimental Study of the Growth Inhibition in Vitro on Human Prostate Cancer Cell Line PC-3M by TRAIL[J]. Cancer Research on Prevention and Treatment, 2004, 31(07): 395-397. DOI: 10.3971/j.issn.1000-8578.273
    [8]SU Han wen, LI Yan, XU Pu. The study of diagnosis of complexed prostate-specific antigen for prostate cancer[J]. Cancer Research on Prevention and Treatment, 2003, 30(03): 198-199. DOI: 10.3971/j.issn.1000-8578.2730
    [9]DANG Cheng-xue, HAN Yue, QIN Zhao-ying, et al. Clinical Significance of Expressions of p21 and p53 Proteins and PCNA in Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2000, 27(04): 262-263. DOI: 10.3971/j.issn.1000-8578.691
    [10]Zhu Zhendao, . Expression of bcl-2,p53 and c-erb-B2 in Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 1998, 25(4): 273-275.

Catalog

    TANG Xu

    1. On this Site
    2. On Google Scholar
    3. On PubMed
    Article views (2320) PDF downloads (769) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return